Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives $166.00 Consensus Target Price from Analysts

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received an average recommendation of “Hold” from the nineteen research firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $166.00.

A number of equities research analysts have issued reports on JAZZ shares. Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating and set a $138.00 target price for the company. in a research note on Friday, September 13th. ValuEngine raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Oppenheimer set a $176.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, September 26th. Evercore ISI reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, November 11th. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 14th.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $130.00, for a total transaction of $65,000.00. Following the completion of the transaction, the chief executive officer now owns 311,855 shares of the company’s stock, valued at approximately $40,541,150. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC lifted its position in Jazz Pharmaceuticals by 28.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,555,801 shares of the specialty pharmaceutical company’s stock worth $364,355,000 after acquiring an additional 562,700 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 4,979.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,924,270 shares of the specialty pharmaceutical company’s stock worth $274,324,000 after purchasing an additional 1,886,384 shares during the period. Boston Partners increased its holdings in shares of Jazz Pharmaceuticals by 2.7% during the 2nd quarter. Boston Partners now owns 1,341,023 shares of the specialty pharmaceutical company’s stock worth $191,116,000 after purchasing an additional 35,360 shares during the period. LSV Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 12.5% during the 2nd quarter. LSV Asset Management now owns 1,127,120 shares of the specialty pharmaceutical company’s stock worth $160,682,000 after purchasing an additional 125,470 shares during the period. Finally, AQR Capital Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 46.9% during the 2nd quarter. AQR Capital Management LLC now owns 1,057,019 shares of the specialty pharmaceutical company’s stock worth $147,496,000 after purchasing an additional 337,396 shares during the period. 88.52% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:JAZZ traded up $0.28 during trading on Friday, reaching $138.90. 603,909 shares of the company traded hands, compared to its average volume of 550,265. The firm has a fifty day simple moving average of $125.83 and a 200 day simple moving average of $131.94. The firm has a market cap of $7.84 billion, a P/E ratio of 11.35, a price-to-earnings-growth ratio of 1.08 and a beta of 1.09. Jazz Pharmaceuticals has a 1-year low of $113.52 and a 1-year high of $154.44. The company has a quick ratio of 3.71, a current ratio of 3.89 and a debt-to-equity ratio of 0.56.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.19 by $0.91. The company had revenue of $537.70 million during the quarter, compared to analyst estimates of $523.92 million. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same quarter last year, the business posted $3.58 EPS. As a group, research analysts anticipate that Jazz Pharmaceuticals will post 14.15 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: How to calculate the annual rate of depreciation

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.